marijuana stocks news

Easton Pharmaceuticals Releases Preliminary Vaporizer Related Sales of $25,638.00 in the Month of November

NEW YORK, NY–(Marketwired – Dec 15, 2014) – Easton Pharmaceuticals (OTC PINK: EAPH) Is pleased to announce details on its Vaporizer units progress with sales of $25,638.00 for the month of November.

Month end inventory on hand was shown at $10,670.00 for its vaporizer unit. Vaporizers were not Easton’s primary goal when it entered into the Medical Marijuana Industry. However, the company has been able to leverage its vaporizer unit to negotiate with Legal Marijuana Prescription Services Businesses.

Its first sale of a Vaporizer was made on the first day of its website launch and was for a ZEDS vaporizer unit. Since that date sales have been progressing at a steady pace, Cyber week provided an additional catalyst for sales in November. Currently the most popular brands have been the following units:

The HEBE 2.0 is a robust vaporizing instrument featuring an intuitive temperature control system. It offers a wide-mouth heating chamber for easy loading and cleaning and features a durable and rugged rubberized exterior.

The DaVinci Vaporizer combines a feature rich platform with rugged portability. Our most popular model in the DaVinci line, which is offered in a very appealing and popular black matte finish.

The company believes it has already received a good return on its conservative investments made on its vaporizer Initiative. Future sales cannot be accurately estimated but testing has shown that Vaporizer retail Location(s) in the Greater Toronto Area along with a New York City location would both be viable initiatives. The company believes utilizing these retail locations as multi purpose facilities in the selling of products and services such as Vaporizers, OTC products, and a Marijuana Prescription Service would be successful. This could lead towards its ultimate goal of acquiring a database of Legal Canadian Medical Marijuana patients which the company has initiated discussion on. Monetizing of these patients could be made in two ways which would include subscription fee’s alongside an administrative fee it would charge any currently Licensed Providers.

About Easton Pharmaceuticals

Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic / cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development. The company has ventured into the medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and maintains an exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The “Act”). In particular, when certain words or phrases such as “hope”, “positive”, “anticipate,” “pleased,” “plan,” “confident that,” “believe,” “expect,” “possible” or “intent to” and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company’s products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company’s financial reports and filings.

Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
1 comment
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$INSY Initiates Five Phase III Clinical Trials

Insys Therapeutics to Initiate Five Phase III Clinical Trials in 2015 PHOENIX,…

GW Pharmaceuticals plc (GWPH) Announces Acceptance of NDA Filing for Epidiolex®

GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex® (cannabidiol) in the…

Cresco Labs (CRLBF) Reaches 60 Nationwide Dispensaries with the Opening of Two Florida Stores

Cresco Labs Reaches 60 Nationwide Dispensaries with the Opening of Two Florida…

Hemp, Inc. (HEMP) Applauds Advancement of Hemp Bills in Indiana

Hemp, Inc. Applauds Advancement of Hemp Bills in Indiana Hemp, Inc. (OTC PINK:…